Vyome Holdings, Inc.
HINDVyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.
- Revenue
- +67.6%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
Follow HIND
Alert me
Vyome Holdings, Inc. (HIND) Return on invested capital
Vyome Holdings, Inc.'s return on invested capital over the twelve months to Sep 30, 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −3,384.9% (fiscal 2017) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 456.96 |
| FY2023 | −457.0% | (456.96) |
| FY2022 | 0.00% | 165.96 |
| FY2021 | −166.0% | (133.86) |
| FY2020 | −32.1% | 464.78 |
| FY2019 | −496.9% | (496.88) |
| FY2018 | 0.00% | 3,384.94 |
| FY2017 | −3,384.9% | (3,384.94) |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| BIVI BioVie Inc. compare | 0.00% |
| HIND Vyome Holdings, Inc. | 0.00% |
| AEON AEON Biopharma, Inc. compare | 0.00% |
| LSTA Lisata Therapeutics, Inc. compare | 0.00% |
| TCRX TScan Therapeutics, Inc. compare | 0.00% |
| LEXX Lexaria Bioscience Corp. compare | −662.6% |
| GDTC CytoMed Therapeutics Limited compare | — |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| PBM Psyence Biomedical Ltd. compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.06% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)